SCHEMBL20545177

SCHEMBL20545177

COC(=O)CCCCCSc1ccccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 8/20 0.48
▸ MEN1 O00255 2/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ GAA P10253 1/20 0.45
▸ RAB9A P51151 1/20 0.43
▸ MAPT P10636 3/20 0.43
▸ LMNA P02545 1/20 0.42
▸ POLB P06746 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17045927 0.84 EPHX2 (0.52) PTGS2MEN1ALDH1A1KMT2ARAB9A
SCHEMBL20545021 0.83 PTGS2 (0.48) PTGS2MEN1ALDH1A1KMT2ARAB9A
SCHEMBL20545058 0.83 MTNR1A (0.58) PTGS2MEN1ALDH1A1KMT2ARAB9A
SCHEMBL4269742 0.82 PTGS2 (0.59) PTGS2MEN1ALDH1A1KMT2AGAA
SCHEMBL4273902 0.82 PTGS2 (0.59) PTGS2MEN1ALDH1A1KMT2AGAA
SCHEMBL17052733 0.82 PTGS2 (0.50) PTGS2MEN1ALDH1A1KMT2ARAB9A
SCHEMBL17045909 0.82 HSD17B10 (0.65) PTGS2MEN1ALDH1A1KMT2ARAB9A
SCHEMBL26445665 0.82 PTGS2 (0.50) PTGS2MEN1ALDH1A1KMT2AGAA
SCHEMBL17056828 0.81 HDAC1 (0.64) MEN1KMT2A
SCHEMBL4273503 0.80 PTGS2 (0.57) PTGS2MEN1ALDH1A1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12478594-B2 Methods of treatment of kidney injury associated with infection or trauma University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2025-11-25 — — US disclosed
US-20220226266-A1 Methods of Treatment of Kidney Injury Associated with Infection or Trauma NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-07-21 — — US disclosed
WO-2020240524-A2 METHODS OF TREATMENT OF KIDNEY INJURY ASSOCIATED WITH INFECTION OR TRAUMA UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2020-12-03 — — WO disclosed
US-20200207691-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury UNIVERSITY OF PITTSBURGH - OF T 2020-07-02 — — US disclosed
US-20200207691-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury UNIVERSITY OF PITTSBURGH - OF T 2020-07-02 — — US disclosed
US-10626071-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2020-04-21 — — US disclosed
US-10626071-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2020-04-21 — — US disclosed
US-10160705-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2018-12-25 — — US disclosed
US-20180312455-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2018-11-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10160705-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury HDAC1, HDAC9, HDAC11 PTGS2 1823/4885MEN1 4549/4885ALDH1A1 351/4885
US-20220226266-A1 Methods of Treatment of Kidney Injury Associated with Infection or Trauma MMP8, PLAU, KLKB1 PTGS2 385/4885MEN1 3286/4885ALDH1A1 2405/4885
US-10626071-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury HDAC1, HDAC9, HDAC11 PTGS2 1823/4885MEN1 4549/4885ALDH1A1 351/4885
US-20180312455-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury HDAC1, HDAC9, HDAC11 PTGS2 1823/4885MEN1 4549/4885ALDH1A1 351/4885
US-20200207691-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury HDAC1, HDAC9, HDAC11 PTGS2 1823/4885MEN1 4549/4885ALDH1A1 351/4885
US-12478594-B2 Methods of treatment of kidney injury associated with infection or trauma HDAC1, HDAC2, HDAC4 PTGS2 889/4885MEN1 4252/4885ALDH1A1 1054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback